Fund Overview
Performance
as at 30/11/20231
1 Month | 3 Month | 6 Months | 1 Year | 3 Years (pa) | 5 Years (pa) | 7 Years (pa) | 10 Years (pa) | Since Inception (pa)2 | |
---|---|---|---|---|---|---|---|---|---|
Total Return % | -0.41 | -1.19 | 2.15 | 9.39 | 11.31 | 9.04 | 8.10 | 8.10 | 7.62 |
Average Market Exposure4 | 57% | 57% | 58% | 57% | 56% | 57% | 58% | 59% | 61% |
1 Fund Returns are calculated after fees and expenses and assume the reinvestment of distributions.
2 Inception date for performance calculation is 1 October 2005.
3 Past performance is not a reliable indicator of future performance.
4 Average Market Exposure calculated on delta-adjusted exposure of underlying portfolio.
Distribution History
Frequency | End Period | Cents per Unit | Reinvestment Price |
---|---|---|---|
Quarterly | 30-Sept-23 | 5.80605 | $5.4423 |
Quarterly | 30-Jun-23 | 8.1576 | $5.3852 |
Quarterly | 31-Mar-23 | 5.370 | $5.308 |
Quarterly | 30-Dec-22 | 5.45749 | $5.1011 |
Quarterly | 30-Sept-22 | 8.97251 | $4.9652 |
Quarterly | 30-Jun-22 | 14.1354 | $5.0013 |
Quarterly | 31-Mar-22 | 5.5215 | $5.0036 |
Quarterly | 31-Dec-21 | 5.2967 | $5.0779 |
Quarterly | 30-Sep-21 | 6.1245 | $5.000 |
Quarterly | 30-Jun-21 | 8.876 | $4.918 |
Growth of $100,000 since inception6

Annual Distributions7

6 Calculations are based on exit price, net of management fees and expenses and assumes reinvestment of distributions. Past performance is not a reliable indicator of future performance. 7 Illustrates Distribution Returns for the Talaria Global Equity Fund – Foundation Units for the financial year ending 30 June 2023. Inception date is 1 October 2005.
Top 10 holdings8
Company Name | Holding % | Country | Sector | Description |
---|---|---|---|---|
Sanofi | 6.2 | France | Healthcare | Top 5 pharmaceutical firm with leading positions in diabetes and rare diseases |
Gilead | 5.2 | USA | Healthcare | Leading research based biopharmaceutical company |
Roche | 5.1 | Switzerland | Healthcare | A global leader in cancer treatments |
Secom | 5.1 | Japan | Consumer Discretionary | Japan’s largest protective and electronic security solutions provider |
Johnson & Johnson | 5.1 | USA | Healthcare | Pharmaceutical, medical devices and consumer health products company |
KDDI Corporation | 4.8 | Japan | Communication Services | The second largest Telco in Japan with significant market share in payments and data centres |
Sodexo | 4.1 | France | Consumer Discretionary | A multinational food services and facilities management company |
Nippon Telegraph & Telephone Corp | 4.0 | Japan | Communication Services | Japan’s largest telecommunications provider |
Henry Schein | 3.7 | USA | Healthcare | American distributor of health care products and services with a presence in 32 countries |
Novartis | 3.5 | Switzerland | Healthcare | One of the world’s largest pharmaceutical companies |
8 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.
Sector allocation9
Regional Allocation10
9,10 Weightings include option positions held and cash backing put options. It assumes that put options will be exercised. Should the put option not be exercised the cash will revert to the unencumbered cash portfolio or may be used to cover further put options.
*USA includes American Depositary Receipts (ADRs) listings.
Fund Snapshot
Management Fee | Nil |
Liquidity | Daily |
Min Investment | $50,000 |
Availability | Wholesale Clients Only |
Inception Date | 1 October 2005 |
Buy / Sell Spread | 0.20% / 0.20% |
Distributions | Quarterly |
Wholesale Investor Confirmation
By clicking below you are confirming that you are an Australian wholesale client for the purposes of section 761G of the Corporations Act 2001. Access to this information is provided on the condition that it is not passed on to any person who is a retail client within the meaning of section 7610 of the Corporations Act 2001.